Preliminary results on mechanisms of resistance to ALK inhibitors: A prospective cohort from the MATCH-R study

Date 14 September 2018
Event MAP 2018 - Molecular Analysis for Personalised Therapy
Session Clonal evolution
Presenter Gonzalo Recondo
Citation Annals of Oncology (2018) 29 (ersion="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publi
Authors G. Recondo1, L. Mezquita2, L. Bigot1, J. Galissant1, R.L. Frias1, F. André2, C. Massard3, J. Soria4, B. Besse2, L. Friboulet1
  • 1Inserm U981, Gustave Roussy Cancer Campus, Université Paris-Sud, 94805 - Villejuif/FR
  • 2Department Of Medical Oncology, Inserm U981, Gustave Roussy Cancer Campus, 94805 - Villejuif/FR
  • 3Ditep, Gustave Roussy Cancer Campus, 94805 - Villejuif/FR
  • 4Medimmune, 20878 - Gaithersburg/US


ALK tyrosine kinase inhibitors (TKIs) have shown to be effective in the treatment of patients with ALK rearranged NSCLC. The clinical benefit is eventually limited by the acquisition of resistance to ALK TKIs by tumor cells. The study of the biological mechanisms implied in tumor progression can provide the rational for therapeutic strategies to overcome resistance.